Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease

Reuters12-01
Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics Inc. has announced plans for a Phase 3 registrational program evaluating zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. The study will enroll participants with lower plasma p-tau217 levels, a strategy supported by the U.S. Food and Drug Administration (FDA) following an end-of-Phase 2 meeting in July 2025. The Phase 3 program will consist of two six-month studies, with participants randomized to receive either 100 mg of oral zervimesine or placebo daily. Efficacy will be measured using the iADRS scale. Results from the Phase 2 "SHINE" study, previously presented, indicated that zervimesine slowed cognitive decline in patients with lower p-tau217 levels. Details of the Phase 3 trial design were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference held December 1-4, 2025. Cognition Therapeutics is also seeking alignment with the European Medicines Agency $(EMA)$ regarding their global registrational plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593837-en) on December 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment